Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHAG in Elderly or Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT07507825Phase 2Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Cytokines & Interferons, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, homoharringtonine, azacitidine, filgrastim in acute myeloid leukemia (AML), sponsored by Hangzhou First People's Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
venetoclaxhomoharringtonineazacitidinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07507825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507825.